Floatz logo

Thiotepa

Common Variable Immunodeficiency

University of FloridaSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Common Variable Immunodeficiency cohort.

Asset / SponsorPhaseRating
Conestat Alfa
IMMUNOe Research Centers
Phase 4BB
Human Immunoglobulins
Grifols Therapeutics LLC
Phase 3B
Melphalan
Paul Szabolcs
Phase 2CCC
Fludarabine
Paul Szabolcs
Phase 2CCC
Alemtuzumab
Paul Szabolcs
Phase 2CCC

View all 18 →

Same molecule, other indications

Thiotepa is also rated in:

graft versus host diseaseActive
BBB
Indicative · Phase 4
73 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
72 / 100
View asset →
juvenile myelomonocytic leukemiaActive
BBB
Indicative · Phase 3
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →